Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis
Erik R. Kline PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorSusan Muller DMD
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorLin Pan MS
Department of Biostatistics, Emory University, Atlanta, Georgia
Search for more papers by this authorMourad Tighiouart PhD
Department of Biostatistics, Emory University, Atlanta, Georgia
Search for more papers by this authorZhuo (Georgia) Chen PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorCorresponding Author
Adam I. Marcus PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GeorgiaSearch for more papers by this authorErik R. Kline PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorSusan Muller DMD
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorLin Pan MS
Department of Biostatistics, Emory University, Atlanta, Georgia
Search for more papers by this authorMourad Tighiouart PhD
Department of Biostatistics, Emory University, Atlanta, Georgia
Search for more papers by this authorZhuo (Georgia) Chen PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Search for more papers by this authorCorresponding Author
Adam I. Marcus PhD
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, Georgia
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GeorgiaSearch for more papers by this authorAbstract
Background
LKB1 loss is associated with invasive carcinoma and metastasis. In head and neck squamous cell carcinoma (HNSCC), lymph node metastasis status is the strongest predictor of survival.
Methods
LKB1 immunohistochemistry was performed on primary tumors from patients with HNSCC who never developed metastases, patients with metastases, and their paired lymph node metastasis to determine whether LKB1 was associated with HNSCC metastasis.
Results
LKB1 was expressed in the nucleus and cytoplasm of tumor cells and HNSCC cell lines. Primary tumors from patients with metastatic carcinoma had decreased nuclear, but not cytoplasmic, LKB1 compared to patients with nonmetastatic cancer. Nuclear LKB1 levels correlated with lymph node metastasis grade and primary tumor site. The percentage of tumor cells negative for nuclear LKB1 staining was greatest in the primary metastatic tumor group, and decreased nuclear LKB1 trended toward worse disease-free survival.
Conclusion
Decreased nuclear LKB1 levels correlate with HNSCC metastasis and suggest a nuclear function of LKB1 in repressing HNSCC metastasis. Head Neck, 2010
REFERENCES
- 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
- 2 Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922–935.
- 3 Kurtulmaz SY, Erkal HS, Serin M, Elhan AH, Cakmak A. Squamous cell carcinomas of the head and neck: descriptive analysis of 1293 cases. J Laryngol Otol 1997; 111: 531–535.
- 4 Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg 1990; 103: 14–24.
- 5 Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005; 16 Suppl 6: vi7–vi12.
- 6
Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB.
Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma.
Cancer
1993;
71:
452–456.
10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 7 Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448–456.
- 8 Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
- 9 Baas AF, Kuipers J, van der Wel NN, et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116: 457–466.
- 10 Zhang S, Schafer-Hales K, Khuri FR, Zhou W, Vertino PM, Marcus AI. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res 2008; 68: 740–748.
- 11 Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807–810.
- 12 Cheng H, Liu P, Wang ZC, et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009; 2: ra35.
- 13 Smith DP, Spicer J, Smith A, Swift S, Ashworth A. The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum Mol Genet 1999; 8: 1479–1485.
- 14 Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75: 137–163.
- 15 Zeng PY, Berger SL. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res 2006; 66: 10701–10708.
- 16 Nath-Sain S, Marignani PA. LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol Biol Cell 2009; 20: 2785–2795.
- 17 Sebbagh M, Santoni MJ, Hall B, Borg JP, Schwartz MA. Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol 2009; 19: 37–42.
- 18 Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. Embo J 2003; 22: 3062–3072.
- 19 Boudeau J, Baas AF, Deak M, et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. Embo J 2003; 22: 5102–5114.
- 20 Dorfman J, Macara IG. STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. Mol Biol Cell 2008; 19: 1614–1626.
- 21 Ghaffar H, Sahin F, Sanchez-Cepedes M, et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res 2003; 9: 2998–3003.
- 22 Sahin F, Maitra A, Argani P, et al. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol 2003; 16: 686–691.
- 23 Wei C, Amos CI, Rashid A, et al. Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. J Histochem Cytochem 2003; 51: 1665–1672.
- 24 Fenton H, Carlile B, Montgomery EA, et al. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006; 14: 146–153.
- 25 Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 2004; 23: 4037–4040.
- 26 Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659–3662.
- 27 Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069–1075.
- 28 Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009; 4: e5137.
- 29 Qiu W, Schönleben F, Thaker HM, Goggins M, Su GH. A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma. Oncogene 2006; 25: 2937–2942.
- 30 Wreesmann VB, Wang D, Goberdhan A, et al. Genetic abnormalities associated with nodal metastasis in head and neck cancer. Head Neck 2004; 26: 10–15.
- 31 Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981; 41: 1657–1663.
- 32 Zhang X, Hunt JL, Landsittel DP, et al. Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res 2004; 10: 8451–8459.
- 33 Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou MH. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 2008; 283: 12446–12455.
- 34 Xie Z, Dong Y, Zhang J, Scholz R, Neumann D, Zou MH. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol Cell Biol 2009; 29: 3582–3596.
- 35 Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283: 27628–27635.
- 36 Mehenni H, Lin-Marq N, Buchet-Poyau K, et al. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 2005; 14: 2209–2219.
- 37 Marignani PA, Kanai F, Carpenter CL. LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J Biol Chem 2001; 276: 32415–32418.
- 38 Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548–558.
- 39 Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374–383.
- 40 Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008; 25: 621–628.
- 41 Oltean S, Sorg BS, Albrecht T, et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A 2006; 103: 14116–14121.
- 42 Guervós MA, Marcos CA, Hermsen M, Nuño AS, Suárez C, Llorente JL. Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas. Cell Oncol 2007; 29: 327–334.
- 43 Hosogi H, Nagayama S, Kawamura J, et al. Molecular insights into Peutz-Jeghers syndrome: two probands with a germline mutation of LKB1. J Gastroenterol 2008; 43: 492–497.
- 44 Amin RM, Hiroshima K, Miyagi Y, et al. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung. Pathol Int 2008; 58: 38–44.
- 45 Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004; 4: 65.
- 46 Kato N, Romero M, Catasus L, Prat J. The STK11/LKB1 Peutz-Jegher gene is not involved in the pathogenesis of sporadic sex cord-stromal tumors, although loss of heterozygosity at 19p13.3 indicates other gene alteration in these tumors. Hum Pathol 2004; 35: 1101–1104.
- 47 Trojan J, Brieger A, Raedle J, Esteller M, Zeuzem S. 5′-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut 2000; 47: 272–276.
- 48 Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159: 2017–2022.
Citing Literature
